Obesity treatment as part of all-Russian observational safe weight loss program «PrimaVera» in Tomsk
AbstractIn Russia more than 25% of obese individuals and more than 55% are overweight. Obesity increases the risk of the development of hypertension, diabetes mellitus type 2, arthragra, cancer and cardiovascular diseases, and also reduces longevity. From october 2012 to the present day under the guidance of Endocrinology Research Center conducted All-Russia Non-interventional Program of Reduxine Safety Monitoring for Weight Reduction in Patients With Alimentary Obesity in the Routine Clinical Practice – «PrimaVera». This article presents results obtained in Tomsk clinical centers.
Keywords:PrimaVera, Reduxin®, obesity, diabetes mellitus, cardiovascular diseases
Endocrinology: News, Opinions, Training. 2014; (3): 93–95.